← All trials
NCT06411691
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 4, 2024
- Primary completion
- Nov 30, 2027
- Completion date
- Nov 30, 2027
- First posted
- May 13, 2024
- Last posted
- Nov 15, 2024
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Johns Hopkins UniversityLead sponsor
- National Institutes of Health (NIH)Collaborator
- Johns Hopkins UniversityOfficial
- Agenus Inc.Collaborator
- National Cancer Institute (NCI)Collaborator
- Department of DefenseCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.